Kura Oncology, Inc. (KURA)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy KURA limit 11.40 (GTC): pullback-to-support within an intact uptrend — price above the SMA50 (11.17) and SMA200 (9.82) after a -21% retrace that held 11.03–11.14 support with a 09-17 bullish reversal bar. Protective stop 10.81 (Change-A pullback floor = entry − 1.0×ATR14 0.59; structural stop swingLow 11.025 − 0.12 buffer = 10.91 was tighter and widened to the floor). Targets 12.58 (+2.0×ATR) and 13.47 (+3.5×ATR); R/R 2.00. No earnings/dividend/split events inside the 15-trading-day holding window (next confirmed earnings 2026-11-03, beyond horizon 2026-10-09); liquidity, overnight-gap, minimum-ATR and trend-alignment gates all passed. Breakout buy-stop above 12.20 rejected (R/R 0.88 < 1.0); market entry rejected (overhead 12.20 within 1×ATR, no confirmed breakout in progress).
Company overview
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its lead product, KOMZIFTI (ziftomenib), is an FDA-approved menin inhibitor for relapsed/refractory NPM1-mutated AML. The company also explores other therapies for solid tumors and cardiometabolic disorders.
Fundamental
fairKura has strong liquidity and an FDA-approved product, but remains loss-making and cash-flow negative.
Mixed fundamentals: strong liquidity runway and an FDA-approved launch, but the company remains materially loss-making and cash-flow negative. Intrinsic-value and analyst-target signals point higher, yet execution risk (commercial uptake, regulatory, and pipeline outcomes) remains the dominant driver.
Sentiment
fairSentiment is modestly positive, buoyed by a recent subsidiary spinout, but lacks a forward catalyst.
Dominant near-term driver is the announced Caspian Therapeutics spinout (2026-09-09, announced, bullish on net-positive ~+0.4 media reception) alongside a determinate mildly positive sentiment delta (+0.07 baseline → +0.20 scoring); Red-Flag Screen clean with no severe or moderate flags. The catalyst is trailing and only partially priced with no forward-dated driver and no retail confirmation, so this is a constructive, forming setup rather than a top-band actionable one.
Technical
goodThe stock is in a pullback-to-support within an uptrend, with price holding above key moving averages.
Pullback-to-support within an intact uptrend: price (11.72) holds above the rising SMA50 (11.17) and SMA200 (9.82) after a -21% three-week retrace from the 13.90 high, the 11.03–11.14 support zone held, and 09-17 printed a bullish reversal bar (+2.9% off a 11.35 low) with three consecutive higher lows (11.03 → 11.14 → 11.35). Momentum is improving (RSI 43.2→48.5, Williams %R -92.9→-75.0, MACD histogram -0.27→-0.21) though still sub-zero. One weak signal: price remains below the SMA20 (12.34)/EMA21 (11.84) fast-average stack with a negative MACD histogram, so reversal confirmation is still forming — the limit entry at 11.40 buys the retest of the reversal zone rather than chasing the 09-17 bounce. Liquidity, overnight-gap, minimum-ATR, event-window and trend-alignment gates all pass. Score 4 (strong setup, one weak signal).
You’re looking at 2026-09-18 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.